Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors

PURPOSE: To evaluate the outcomes and prognostic factors for patients using conversion therapy with lenvatinib combined with transcatheter arterial chemoembolization (TACE) plus programmed cell death protein-1 (PD-1) inhibitors (LTP) for initially unresectable hepatocellular carcinoma (iuHCC). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xingzhi, Chen, Jie, Wang, Xiaobo, Bai, Tao, Lu, Shaolong, Wei, Tao, Tang, Zhihong, Huang, Chengwen, Zhang, Bin, Liu, Bowen, Li, Lequn, Wu, Feixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923097/
https://www.ncbi.nlm.nih.gov/pubmed/36793614
http://dx.doi.org/10.3389/fonc.2023.1110689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923097/
https://www.ncbi.nlm.nih.gov/pubmed/36793614
http://dx.doi.org/10.3389/fonc.2023.1110689

Ejemplares similares